#1 Clinical Trials Search in Europe

Envudeucitinib

Envudeucitinib, also known as ESK-001, is a promising new drug being studied for the treatment of moderate to severe plaque psoriasis. This article explores the ongoing clinical trials investigating the effectiveness and safety of this medication compared to placebo and an active comparator, apremilast. We’ll discuss the trial design, eligibility criteria, and expected outcomes of this important research.

Table of Contents

What is ENVUDEUCITINIB?

ENVUDEUCITINIB, also known as ESK-001 or FTP-637, is a new medication being studied for the treatment of moderate to severe plaque psoriasis. Plaque psoriasis is a chronic skin condition characterized by red, scaly patches on the skin that can be itchy and painful[1].

This drug is currently undergoing a Phase 3 clinical trial, which is an advanced stage of testing to determine its effectiveness and safety in treating psoriasis[1].

How Does It Work?

ENVUDEUCITINIB belongs to a class of drugs known as TYK2 inhibitors. TYK2 stands for Tyrosine Kinase 2, which is an enzyme involved in the inflammatory processes that contribute to psoriasis. By inhibiting this enzyme, ENVUDEUCITINIB may help reduce inflammation and improve psoriasis symptoms[1].

Clinical Trial Details

The ongoing clinical trial, named ONWARD1, is designed to evaluate how well ENVUDEUCITINIB works compared to a placebo (a substance with no active ingredients) and another psoriasis medication called apremilast[1].

Key points about the trial:

  • It’s a multicenter, randomized, double-blind study. This means it’s being conducted at multiple locations, participants are randomly assigned to different treatment groups, and neither the participants nor the researchers know who is receiving which treatment[1].
  • The trial lasts for 24 weeks, with the primary evaluation point at 16 weeks[1].
  • Participants take the medication orally (by mouth) twice daily[1].

Who Can Participate in the Trial?

The trial is open to adults (18 years and older) with moderate to severe plaque psoriasis. Some key eligibility criteria include[1]:

  • Having had plaque psoriasis for at least 6 months
  • Psoriasis plaques covering at least 10% of the body surface area
  • A certain level of psoriasis severity as measured by standard scales (PASI and sPGA)

However, there are also several conditions that would exclude someone from participating, such as having certain other medical conditions or having used specific psoriasis treatments recently[1].

Potential Benefits

The main goals of the study are to determine if ENVUDEUCITINIB can[1]:

  • Improve psoriasis symptoms better than a placebo
  • Work as well as or better than apremilast, an existing psoriasis treatment
  • Reduce the area of skin affected by psoriasis
  • Improve quality of life for people with psoriasis
  • Reduce itching associated with psoriasis

Safety Considerations

As with any new medication, safety is a crucial aspect of the study. The researchers will be closely monitoring participants for any side effects or adverse reactions throughout the trial[1].

It’s important to note that because this is an investigational drug, not all potential side effects may be known at this time. This is why careful monitoring and reporting of any health changes during the trial is crucial[1].

If ENVUDEUCITINIB proves to be safe and effective in this trial, it could potentially offer a new treatment option for people with moderate to severe plaque psoriasis in the future[1].

Aspect Details
Drug Name Envudeucitinib (ESK-001)
Condition Studied Moderate to Severe Plaque Psoriasis
Trial Phase Phase 3
Main Objective Determine if ESK-001 is superior to placebo at Week 16
Secondary Objectives Compare ESK-001 to apremilast, assess safety and tolerability, characterize pharmacokinetics
Trial Duration 24 weeks (16-week Treatment Period + 8-week Maintenance Period)
Dosage 40 mg twice daily
Primary Endpoints Achievement of PASI-75 & sPGA-0/1 at Week 16 compared to Placebo
Key Inclusion Criteria Adults ≥18 years, plaque psoriasis for ≥6 months, ≥10% BSA affected, PASI ≥12, sPGA ≥3
Key Exclusion Criteria Non-plaque psoriasis, recent serious infections, immunodeficiency, certain lab abnormalities, recent use of specific psoriasis treatments

FAQ

  • What is Envudeucitinib (ESK-001)? Envudeucitinib, also known as ESK-001, is a new drug being studied for the treatment of moderate to severe plaque psoriasis. It is taken orally as a tablet and is being tested to see if it can effectively reduce psoriasis symptoms.
  • What is the main goal of the clinical trial? The main goal of the trial is to determine if ESK-001 is more effective than a placebo in treating moderate to severe plaque psoriasis after 16 weeks of treatment. The study also aims to compare ESK-001's effectiveness to apremilast, another psoriasis medication.
  • Who can participate in this clinical trial? The trial is open to adults (18 years and older) who have been diagnosed with plaque psoriasis for at least 6 months. Participants must have psoriasis plaques covering at least 10% of their body surface area and meet certain severity criteria. However, there are several exclusion criteria, such as having other inflammatory skin conditions or certain medical histories.
  • How long does the clinical trial last? The clinical trial consists of two main periods: a 16-week Treatment Period and an 8-week Maintenance Period, for a total duration of 24 weeks (about 6 months).
  • What are the potential benefits and risks of participating in this trial? Potential benefits include access to a new treatment that may improve psoriasis symptoms. However, as with any clinical trial, there are risks, including possible side effects of the medication. The trial is designed to assess both the effectiveness and safety of ESK-001. Participants will be closely monitored throughout the study to manage any potential risks.

Ongoing Clinical Trials on Envudeucitinib

  • Study on the Effectiveness and Safety of ESK-001 and Apremilast for Adults with Moderate to Severe Plaque Psoriasis

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Czechia Germany Poland Portugal

  • Study on Long-term Safety and Effectiveness of ESK-001 for Patients with Moderate to Severe Plaque Psoriasis

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Estonia France +7

  • Study on the Effectiveness and Safety of ESK-001 and Apremilast for Patients with Moderate to Severe Plaque Psoriasis

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Estonia France Germany Hungary Latvia +3

Glossary

  • Plaque Psoriasis: A common form of psoriasis characterized by raised, red patches covered with a silvery white buildup of dead skin cells, typically appearing on the scalp, knees, elbows, and lower back.
  • PASI: Psoriasis Area and Severity Index, a tool used to measure the severity and extent of psoriasis.
  • sPGA: Static Physician's Global Assessment, a scale used to evaluate the overall severity of psoriasis.
  • BSA: Body Surface Area, used to measure the percentage of skin affected by psoriasis.
  • Apremilast: An oral medication used to treat psoriasis and psoriatic arthritis by reducing inflammation.
  • Double-Blind: A study design where neither the participants nor the researchers know who is receiving which treatment, to prevent bias.
  • Placebo: An inactive substance that looks like the drug being tested but has no medical effect.
  • Efficacy: The ability of a treatment to produce the desired result.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • PROs: Patient-Reported Outcomes, assessments of a patient's health condition that come directly from the patient.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-esk-001-and-apremilast-for-adults-with-moderate-to-severe-plaque-psoriasis/